Unknown

Dataset Information

0

Feasibility of dynamic risk assessment for patients with repeated trans-arterial chemoembolization for hepatocellular carcinoma.


ABSTRACT:

Background

Hepatoma arterial-embolization prognostic (HAP) score and its modifications (modified HAP [mHAP] and mHAP-II), consisting of some or all of the following factors of tumor size, number, alpha-fetoprotein, bilirubin, and serum albumin, have been found to predict outcomes after trans-arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). We investigated the feasibility of using HAP-related risk scores for dynamic risk assessment during repeated TACE.

Methods

A total of 619 HCC patients treated with TACE from two institutions between 2003 and 2010 were included.

Results

Patients with A-B class risk scores showed significantly better survival than those with C-D class risk scores at the first (median 43.7 vs. 21.5?months for mHAP-II, 35.2 vs. 10.2?months for mHAP, and 39.8 vs. 18.6?months for HAP; all P?ConclusionsAll HAP-related risk scores dynamically predicted outcomes during repeated TACE. Sequential risk assessment using mHAP-II best identified optimal candidates for repeated TACE.

SUBMITTER: Park Y 

PROVIDER: S-EPMC6469056 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Feasibility of dynamic risk assessment for patients with repeated trans-arterial chemoembolization for hepatocellular carcinoma.

Park Yehyun Y   Kim Beom Kyung BK   Park Jun Yong JY   Kim Do Young DY   Ahn Sang Hoon SH   Han Kwang-Hyub KH   Yeon Jong Eun JE   Byun Kwan Soo KS   Kim Hye Soo HS   Kim Ji Hoon JH   Kim Seung Up SU  

BMC cancer 20190416 1


<h4>Background</h4>Hepatoma arterial-embolization prognostic (HAP) score and its modifications (modified HAP [mHAP] and mHAP-II), consisting of some or all of the following factors of tumor size, number, alpha-fetoprotein, bilirubin, and serum albumin, have been found to predict outcomes after trans-arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). We investigated the feasibility of using HAP-related risk scores for dynamic risk assessment during repeated TACE.<h4>Methods</h4  ...[more]

Similar Datasets

| S-EPMC9697413 | biostudies-literature
| S-EPMC7565721 | biostudies-literature
| S-EPMC8716800 | biostudies-literature
| S-EPMC9391935 | biostudies-literature
| S-EPMC8515486 | biostudies-literature
| S-EPMC5892363 | biostudies-literature
| S-EPMC5708733 | biostudies-literature
| S-EPMC7470052 | biostudies-literature
| S-EPMC3700789 | biostudies-other
| S-EPMC6557480 | biostudies-literature